TY - JOUR T1 - Uncovering the important acoustic features for detecting vocal fold paralysis with explainable machine learning JF - medRxiv DO - 10.1101/2020.11.23.20235945 SP - 2020.11.23.20235945 AU - Daniel M. Low AU - Gregory Randolph AU - Vishwanatha Rao AU - Satrajit S. Ghosh AU - Phillip C. Song Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/18/2020.11.23.20235945.abstract N2 - Objectives To detect unilateral vocal fold paralysis (UVFP) from voice recordings using an explainable model of machine learning.Study Design Case series - retrospective with a control group.Methods Patients with confirmed UVFP through endoscopic examination (N=77) and controls with normal voices matched for age and sex (N=77) were included. Two tasks were used to elicit voice samples: reading the Rainbow Passage and sustaining phonation of the vowel “a”. The 88 extended Geneva Minimalistic Acoustic Parameter Set (eGeMAPS) features were extracted as inputs for four machine learning models of differing complexity. SHAP was used to identify important features.Results The median bootstrapped Area Under the Receiver Operating Characteristic Curve (ROC AUC) score ranged from 0.79 to 0.87 depending on model and task. After removing redundant features for explainability, the highest median ROC AUC score was 0.84 using only 13 features for the vowel task and 0.87 using 39 features for the reading task. The most important features included intensity measures, mean MFCC1, mean F1 amplitude and frequency, and shimmer variability depending on model and task.Conclusion Using the largest dataset studying UVFP to date, we achieve high performance from just a few seconds of voice recordings. Notably, we demonstrate that while similar categories of features related to vocal fold physiology were conserved across models, the models used different combinations of features and still achieved similar effect sizes. Machine learning thus provides a mechanism to detect UVFP and contextualize the accuracy relative to both model architecture and pathophysiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDML was supported by a National Institutes of Health (NIH) training grant (NIDCD 5T32DC000038). The work was supported by a gift to the McGovern Institute for Brain Research at MIT. SSG was partially supported by NIH grant R01 EB020740 (development of pydra-ml) and P41 EB019936 (reproducible practices).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at Massachusetts Eye and Ear Infirmary and Partners Healthcare (IRB 2019002711).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code has been publicly released on Github (https://github.com/danielmlow/vfp) and Zenodo (doi.org/10.5281/zenodo.4287654) https://doi.org/10.5281/zenodo.4287654 https://github.com/danielmlow/vfp ER -